Home › Funds › CDC Financial, Inc. › INBX
CDC Financial, Inc. position in INBX
INHIBRX BIOSCIENCES INC · Health Care
CDC Financial, Inc. reported holding 20,000 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$2.0M, representing 1.09% of its reported portfolio and ranking #18 among its reported holdings. CDC Financial, Inc. has disclosed INBX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How CDC Financial, Inc.'s INBX position evolved
CDC Financial, Inc. first disclosed a stake in INBX in Q4 2025 at 110,810 shares (US$8.8M). Across 4 filings, CDC Financial, Inc. increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 20,000 shares valued at US$2.0M — a reduction of -10,000 shares quarter over quarter.. Notable position changes include a 44% trim in Q1 2026 (shares rose 41% over the following quarter), a 52% trim in Q2 2026 (shares rose 6% over the following quarter), a 33% trim in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 110.81K | $8.75M | New |
| Q1 2026 | 62.00K | $4.17M | Reduce |
| Q2 2026 | 30.00K | $2.84M | Reduce |
| Q3 2026 | 20.00K | $2.00M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 38 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Sanofi (US$115.9M), Schonfeld Strategic Advisors LLC (US$66.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.30M sh · $122.96M · Q2 2026
- Sanofi 1.16M sh · $115.89M · Q3 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- PFM Health Sciences, LP 308.38K sh · $29.22M · Q2 2026
- Sofinnova Investments, Inc. 303.10K sh · $28.72M · Q2 2026
- Parkman Healthcare Partners LLC 256.95K sh · $24.35M · Q2 2026
- First Turn Management, LLC 164.78K sh · $15.61M · Q2 2026
More on CDC Financial, Inc.
FAQ
How long has CDC Financial, Inc. held INBX?
CDC Financial, Inc. has disclosed INBX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is CDC Financial, Inc.'s current position in INBX?
As of Q3 2026, CDC Financial, Inc. holds 20.00K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $2.00M, representing 1.09% of its reported portfolio and ranking #18.
Has CDC Financial, Inc. been buying or selling INBX?
In the latest 13F filing (Q3 2026), CDC Financial, Inc. reduced its position in INBX.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.